Showing posts with label W. Show all posts
Showing posts with label W. Show all posts

Wednesday, October 19, 2016

Wellbutrin XL



Generic Name: bupropion (Oral route)

bue-PROE-pee-on

Oral route(Tablet;Tablet, Extended Release;Tablet, Extended Release, 12 HR;Tablet, Extended Release, 24 HR)

Wellbutrin(R) formulations and Forfivo XL: Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies with major depressive disorder (MDD) and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24, and there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. This risk must be balanced with the clinical need. Monitor patients closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Not approved for use in pediatric patients. Zyban(R): Serious neuropsychiatric events, including depression, suicidal ideation, suicide attempt, and completed suicide, have been reported in patients with and without preexisting psychiatric disease who were taking bupropion for smoking cessation; some experienced worsening of their psychiatric illnesses. All patients should be observed for changes in behavior, hostility, agitation, depressed mood, and suicide-related events, including ideation, behavior, and attempted suicide. The patient should stop taking bupropion and contact a healthcare provider immediately if any neuropsychiatric behavior that is not typical for the patient is observed, or if the patient develops suicidal ideation or suicidal behavior. This risk should be weighed against the benefits of its use .


Oral route(Tablet, Extended Release)

Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies with major depressive disorder (MDD) and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24, and there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. This risk must be balanced with the clinical need. Monitor patients closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Not approved for use in pediatric patients .



Commonly used brand name(s)

In the U.S.


  • Aplenzin

  • Budeprion SR

  • Budeprion XL

  • Buproban

  • Wellbutrin

  • Wellbutrin SR

  • Wellbutrin XL

  • Zyban

Available Dosage Forms:


  • Tablet, Extended Release, 24 HR

  • Tablet, Extended Release, 12 HR

  • Tablet

  • Tablet, Extended Release

Therapeutic Class: Antidepressant


Chemical Class: Aminoketone


Uses For Wellbutrin XL


Bupropion is used to treat mental depression. It is also used as part of a support program to help people stop smoking. This medicine may also be used to prevent depression in patients with seasonal affective disorder, which is sometimes called winter depression.


Bupropion is sold under different brand names for different uses. If you are already taking medicine for mental depression or to help you stop smoking, discuss this with your doctor before taking bupropion. It is very important that you receive only one prescription for bupropion at a time.


This medicine is available only with your doctor's prescription.


Before Using Wellbutrin XL


In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:


Allergies


Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.


Pediatric


Appropriate studies have not been performed on the relationship of age to the effects of bupropion in the pediatric population. Studies with other medicines used for depression have shown that some children, teenagers, and young adults think about suicide or attempt suicide when taking these medicines. Because of this toxicity, use in children is not recommended.


Geriatric


Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of bupropion in the elderly. However, elderly patients may be more sensitive to the effects of this medicine than younger adults, and are more likely to have age-related kidney or liver problems, which may require caution and an adjustment in the dose for patients receiving bupropion.


Pregnancy








Pregnancy CategoryExplanation
All TrimestersCAnimal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women.

Breast Feeding


There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.


Interactions with Medicines


Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.


Using this medicine with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.


  • Clorgyline

  • Iproniazid

  • Isocarboxazid

  • Methylene Blue

  • Metoclopramide

  • Moclobemide

  • Nialamide

  • Pargyline

  • Phenelzine

  • Procarbazine

  • Selegiline

  • Toloxatone

  • Tranylcypromine

Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Betamethasone

  • Budesonide

  • Carbimazole

  • Clobetasone

  • Corticotropin

  • Cortisone

  • Cosyntropin

  • Danazol

  • Deflazacort

  • Desonide

  • Dexamethasone

  • Fludrocortisone

  • Flunisolide

  • Fluticasone

  • Hydrocortisone

  • Linezolid

  • Methenolone

  • Methylprednisolone

  • Methyltestosterone

  • Nandrolone

  • Oxandrolone

  • Oxymetholone

  • Paramethasone

  • Prednisolone

  • Prednisone

  • Rimexolone

  • Stanozolol

  • Testosterone

  • Theophylline

Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Amantadine

  • Citalopram

  • Desipramine

  • Efavirenz

  • Flecainide

  • Fluoxetine

  • Haloperidol

  • Levodopa

  • Lopinavir

  • Metoprolol

  • Nortriptyline

  • Paroxetine

  • Propafenone

  • Risperidone

  • Ritonavir

  • Sertraline

  • St John's Wort

  • Thioridazine

  • Tipranavir

  • Zolpidem

Interactions with Food/Tobacco/Alcohol


Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.


Using this medicine with any of the following is usually not recommended, but may be unavoidable in some cases. If used together, your doctor may change the dose or how often you use this medicine, or give you special instructions about the use of food, alcohol, or tobacco.


  • Ethanol

Other Medical Problems


The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:


  • Alcohol use, if stopped suddenly, or

  • Eating disorders (e.g., anorexia nervosa, bulimia nervosa), history of or

  • Sedative (sleeping medicine) use, if stopped suddenly (e.g., alprazolam [Xanax®], diazepam [Valium®], triazolam [Restoril®]), or

  • Seizures or epilepsy, history of—Should not be used in patients with these conditions.

  • Bipolar disorder (mood disorder with alternating episodes of mania and depression), or risk of or

  • Depression, history of or

  • Hypertension (high blood pressure) or

  • Psychosis (mental disease that affects emotions and behaviors) or

  • Schizophrenia (mental illness)—Use with caution. May make these conditions worse.

  • Brain or spine tumor or

  • Diabetes or

  • Drug or alcohol abuse (e.g., opiates, cocaine, stimulants) or

  • Head injury, history of or

  • Liver disease (including cirrhosis), severe—The risk of seizures may be increased when bupropion is taken by patients with these conditions.

  • Heart attack, recent or

  • Heart disease, unstable—The effects of bupropion in patients with these conditions are not known.

  • Kidney disease or

  • Liver disease—Use with caution. The effects may be increased because of slower removal of the medicine from the body.

  • Mania or hypomania, history of—Use of bupropion may activate these conditions.

Proper Use of bupropion

This section provides information on the proper use of a number of products that contain bupropion. It may not be specific to Wellbutrin XL. Please read with care.


Use bupropion only as directed by your doctor. Do not use more of it, do not use it more often, and do not use it for a longer time than your doctor ordered. To do so, may increase the chance of side effects.


This medicine should come with a Medication Guide. Read and follow these instructions carefully. Ask your doctor if you have any questions.


Use only the brand of this medicine that your doctor prescribed. Different brands may not work the same way.


Swallow the sustained-release tablets whole. Do not break, crush, divide, or chew it.


You may take this medicine with or without food. But, if you have nausea, take this medicine with food.


To lessen stomach upset, this medicine may be taken with food, unless your doctor has told you to take it on an empty stomach.


If you are taking Zyban® tablets to help you stop smoking, you may continue to smoke for about 1 week after you start using this medicine. Then, you should set a target date to quit smoking during your second week of Zyban® treatment. Talk to your doctor if you are having trouble to stop smoking after you have used this medicine for at least 7 weeks.


Do not smoke if you are using a nicotine patch or any other medicine containing nicotine together with Zyban® tablets. To do so, may increase risk for more serious side effects.


This medicine must be taken for several weeks, usually 4 weeks, before you start to feel better. You will probably need to keep taking bupropion for several months to help prevent the return of your depression. Your doctor will check your progress at regular visits, especially during the first few weeks that you take this medicine.


If you have trouble with sleeping (insomnia), do not take this medicine too close to bedtime.


For patients taking the extended-release tablet form of this medicine:


  • Take doses at least 24 hours apart to decrease the chance of seizures.

  • Swallow the tablets whole. Do not crush, break, or chew them.

  • While taking this medicine, part of the tablet may pass into your stools. This is normal and is nothing to worry about.

  • If you use this medicine to prevent depression in seasonal affective disorder, take it during the autumn season before your symptoms start. Continue using this medicine through the winter season and until early spring.

To help you remember to use your medicine, take it at the same time each day.


Dosing


The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.


The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.


  • For oral dosage form (extended-release tablets):
    • For depression:
      • Adults—
        • Aplenzin™: At first, 174 milligrams (mg) once a day in the morning. Your doctor may increase your dose as needed and tolerated. However, the dose is usually not more than 522 mg per day.

        • Forfivo XL®: 450 mg once a day.

        • Wellbutrin XL®: At first, 150 mg once a day in the morning. Your doctor may increase your dose as needed. However, the dose usually is not more than 450 mg once a day.


      • Children—Use and dose must be determined by your doctor.


    • For seasonal affective disorder:
      • Adults—At first, 150 milligrams (mg) once a day in the morning. Your doctor may increase your dose as needed. However, the dose usually is not more than 300 mg once a day.

      • Children—Use and dose must be determined by your doctor.



  • For oral dosage form (tablets):
    • For depression:
      • Adults—At first, 100 milligrams (mg) two times a day. Your doctor may increase your dose as needed. However, the dose is usually not more than 150 mg three times a day. Take doses at least 4 hours apart to decrease the chance of seizures.

      • Children—Use and dose must be determined by your doctor.



  • For oral dosage form (sustained-release tablets):
    • For depression:
      • Adults—At first, 150 milligrams (mg) once a day in the morning. Your doctor may increase your dose as needed. However, the dose usually is not more than 200 mg two times a day. Take doses at least 8 hours apart to decrease the chance of seizures.

      • Children—Use and dose must be determined by your doctor.


    • To help you stop smoking:
      • Adults—At first, 150 milligrams (mg) once a day for the first 3 days. Then, your doctor may increase your dose as needed. However, the dose is usually not more than 300 mg per day. Take doses at least 8 hours apart to decrease the chance of seizures.

      • Children—Use and dose must be determined by your doctor.



Missed Dose


If you miss a dose of this medicine, skip the missed dose and go back to your regular dosing schedule. Do not double doses.


If you are taking the extended-release tablets and you miss a dose, skip the missed dose and go back to your regular dosing schedule.


Storage


Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.


Keep out of the reach of children.


Do not keep outdated medicine or medicine no longer needed.


Ask your healthcare professional how you should dispose of any medicine you do not use.


Precautions While Using Wellbutrin XL


Your doctor will check your progress at regular visits, especially during the first few months that you take this medicine. The amount of bupropion you take may have to be adjusted to meet the needs of your condition and to help avoid unwanted effects.


Do not take bupropion with or within 14 days of taking a drug with monoamine oxidase inhibitor (MAOI) activity (e.g., isocarboxazid [Marplan®], phenelzine [Nardil®], procarbazine [Matulane®], selegiline [Eldepryl®], or tranylcypromine [Parnate®]). Do not take an MAO inhibitor within 14 days of taking bupropion. If you do, you might have convulsions (seizures).


Your blood pressure might get too high while you are using this medicine. This may cause headaches, blurred vision, and other symptoms. You might need to measure your blood pressure at home. If you think your blood pressure is getting too high, call your doctor right away.


Bupropion may cause some people to be agitated, irritable, or display other abnormal behaviors. It may also cause some people to have suicidal thoughts and tendencies or to become more depressed. Make sure the doctor knows if you have trouble sleeping, get upset easily, have a big increase in energy, or start to act reckless. Also tell the doctor if you have sudden or strong feelings, such as feeling nervous, angry, restless, violent, or scared. If you or your caregiver notice any of these side effects, tell your doctor right away.


This medicine may cause a serious type of allergic reaction called anaphylaxis. Anaphylaxis can be life-threatening and requires immediate medical attention. Stop using this medicine and tell your doctor right away if you have a rash; itching; swelling of the face, tongue, and throat; trouble breathing; or chest pain after you take this medicine.


Serious skin reactions can occur with this medicine. Check with your doctor right away if you have blistering, peeling, or loosening of the skin; red skin lesions; severe acne or skin rash; sores or ulcers on the skin; or fever or chills while you are using this medicine.


Drinking alcoholic beverages should be limited or avoided, if possible, while taking bupropion. This will help prevent seizures.


This medicine may cause some people to have a false sense of well-being, or to become drowsy, dizzy, or less alert than they are normally. Make sure you know how you react to this medicine before you drive, use machines, or do anything else that could be dangerous if you are dizzy or not alert and clearheaded.


Do not stop taking this medicine without checking first with your doctor. Your doctor may want you to gradually reduce the amount you are taking before stopping it completely. This is to decrease the chance of having side effects such as agitation, anxiety, dizziness, a feeling of constant movement of self or surroundings, headache, increased sweating, nausea, trembling or shaking, trouble with sleeping or walking, or unusual tiredness when you stop the medicine.


Check with your doctor right away if you have pain or tenderness in the upper stomach; pale stools; dark urine; loss of appetite; nausea; unusual tiredness or weakness; or yellow eyes or skin. These could be symptoms of a serious liver problem.


This medicine may cause changes in your appetite or weight. Your doctor may need to check your weight regularly during treatment with this medicine.


Before you have any medical tests, tell the medical doctor in charge that you are taking this medicine. The results of some tests may be affected by this medicine.


Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements.


Wellbutrin XL Side Effects


Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.


Check with your doctor immediately if any of the following side effects occur:


More common
  • Anxiety

  • dry mouth

  • hyperventilation

  • irregular heartbeats

  • irritability

  • nervousness

  • restlessness

  • shaking

  • shortness of breath

  • trouble with sleeping

Less common
  • Buzzing or ringing in the ears

  • headache (severe)

  • skin rash, hives, or itching

Rare
  • Confusion

  • fainting

  • false beliefs that cannot be changed by facts

  • having extreme distrust of people

  • seeing, hearing, or feeling things that are not there

  • seizures (convulsions)

  • trouble with concentrating

Incidence not known
  • Actions that are out of control

  • anger

  • assaulting others

  • attacking others

  • being aggressive

  • being impulsive

  • chest pain or discomfort

  • fast or pounding heartbeat

  • force

  • inability to sit still

  • need to keep moving

  • sweating

  • talking, feeling, or acting with excitement

Get emergency help immediately if any of the following symptoms of overdose occur:


Symptoms of overdose
  • Blue lips, fingernails, or skin

  • blurred vision

  • change in consciousness

  • dark-colored urine

  • decreased awareness or responsiveness

  • difficult or troubled breathing

  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position

  • fever

  • irregular, fast or slow, or shallow breathing

  • loss of consciousness

  • muscle cramps, pain, or spasms

  • muscle stiffness or tightness

  • nausea

  • severe sleepiness

  • unusual tiredness or weakness

  • vomiting

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:


More common
  • Abdominal or stomach pain

  • constipation

  • decrease in appetite

  • dizziness

  • increased sweating

  • trembling

  • weight loss (unusual)

Less common
  • Blurred vision

  • change in sense of taste

  • drowsiness

  • frequent need to urinate

  • sore throat

  • unusual feeling of well-being

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.


Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: Wellbutrin XL side effects (in more detail)



The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.


The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.


More Wellbutrin XL resources


  • Wellbutrin XL Side Effects (in more detail)
  • Wellbutrin XL Use in Pregnancy & Breastfeeding
  • Drug Images
  • Wellbutrin XL Drug Interactions
  • Wellbutrin XL Support Group
  • 68 Reviews for Wellbutrin XL - Add your own review/rating


  • Wellbutrin XL Extended-Release Tablets MedFacts Consumer Leaflet (Wolters Kluwer)

  • Wellbutrin XL Prescribing Information (FDA)

  • Aplenzin Prescribing Information (FDA)

  • Aplenzin Consumer Overview

  • Aplenzin Extended-Release Tablets MedFacts Consumer Leaflet (Wolters Kluwer)

  • Budeprion XL Prescribing Information (FDA)

  • Bupropion MedFacts Consumer Leaflet (Wolters Kluwer)

  • Bupropion Prescribing Information (FDA)

  • Bupropion Professional Patient Advice (Wolters Kluwer)

  • Bupropion Hydrochloride Monograph (AHFS DI)

  • Wellbutrin Consumer Overview

  • Wellbutrin Prescribing Information (FDA)

  • Wellbutrin SR Sustained-Release Tablets MedFacts Consumer Leaflet (Wolters Kluwer)

  • Wellbutrin SR Prescribing Information (FDA)

  • Zyban Prescribing Information (FDA)

  • Zyban Sustained-Release Tablets MedFacts Consumer Leaflet (Wolters Kluwer)

  • Zyban Consumer Overview



Compare Wellbutrin XL with other medications


  • Depression
  • Seasonal Affective Disorder

Westhroid


Generic Name: thyroid desiccated (THYE roid (DES i kay ted))

Brand Names: Armour Thyroid, Nature-Throid, Westhroid


What is desiccated thyroid?

Desiccated (dried) thyroid is a combination of hormones that are normally produced by your thyroid gland to regulate the body's energy and metabolism. Desiccated thyroid is given when the thyroid does not produce enough of this hormone on its own.


Desiccated thyroid treats hypothyroidism (low thyroid hormone). Desiccated thyroid is also used to treat or prevent goiter (enlarged thyroid gland), and is also given as part of a medical tests for thyroid disorders.


Desiccated thyroid should not be used to treat obesity or weight problems.


Desiccated thyroid may also be used for purposes not listed in this medication guide.


What is the most important information I should know about desiccated thyroid?


Since thyroid hormone occurs naturally in the body, almost anyone can take desiccated thyroid. However, you may not be able to use this medication if you have a thyroid disorder called thyrotoxicosis, or an adrenal gland problem that is not controlled by treatment.

Before taking desiccated thyroid, tell your doctor if you have heart disease, angina (chest pain), coronary artery disease, congestive heart failure, diabetes, or problems with your adrenal glands.


Tell your doctor if you are pregnant or breast-feeding.

To be sure this medication is helping your condition, your blood may need to be tested often. Visit your doctor regularly.


Keep using this medicine as directed, even if you feel well. You may need to take thyroid medication for the rest of your life.


Call your doctor if you notice any signs of thyroid toxicity, such as chest pain, fast or pounding heartbeats, feeling hot or nervous, or sweating more than usual.

What should I discuss with my healthcare provider before taking desiccated thyroid?


Since thyroid hormone occurs naturally in the body, almost anyone can take desiccated thyroid. However, you may not be able to use this medication if you have a thyroid disorder called thyrotoxicosis, or an adrenal gland problem that is not controlled by treatment.

To make sure you can safely take dessicated thyroid, tell your doctor if you have any of these other conditions:



  • heart disease, angina (chest pain);




  • coronary artery disease;




  • congestive heart failure;




  • any type of diabetes; or




  • problems with your adrenal gland.




FDA pregnancy category A. Desiccated thyroid is not expected to be harmful to an unborn baby. However, tell your doctor if you become pregnant, since your dose needs may change. Small amounts of desiccated thyroid can pass into breast milk, but this is not expected to harm a nursing baby. However, do not use this medication without telling your doctor if you are breast-feeding a baby.

How should I take desiccated thyroid?


Take exactly as prescribed by your doctor. Do not take in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.


Your doctor may occasionally change your dose to make sure you get the best results.


To be sure this medication is helping your condition, your blood may need to be tested often. Visit your doctor regularly.


Keep using this medicine as directed, even if you feel well. You may need to take thyroid medication for the rest of your life.


Call your doctor if you notice any signs of thyroid toxicity, such as chest pain, fast or pounding heartbeats, feeling hot or nervous, or sweating more than usual. If you need surgery, tell the surgeon ahead of time that you are using dessicated thyroid. You may need to stop using the medicine for a short time. Store at room temperature away from moisture and heat.

What happens if I miss a dose?


Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

Overdose symptoms may include headache, sweating, diarrhea, irregular menstrual periods, confusion, weakness, swelling in your hands or feet, fast heart rate, chest pain, feeling short of breath, fainting, or feeling nervous, restless, or irritable.


What should I avoid while taking desiccated thyroid?


If you also take cholestyramine (Prevalite, Questran) or colestipol (Colestid), avoid taking these medications within 4 hours before or after you take desiccated thyroid.


Desiccated thyroid side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Less serious side effects may include temporary hair loss (especially in children).


This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect desiccated thyroid?


Tell your doctor about all other medicines you use, especially:



  • birth control pills or hormone replacement therapy;




  • a blood thinner such as warfarin (Coumadin);




  • insulin or diabetes medication you take by mouth;




  • medications that contain iodine (such as I-131);




  • salicylates such as aspirin, Backache Relief Extra Strength, Novasal, Nuprin Backache Caplet, Doan's Pills Extra Strength, Tricosal, and others; or




  • steroids such as prednisone and others.



This list is not complete and other drugs may interact with dessicated thyroid. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.



More Westhroid resources


  • Westhroid Side Effects (in more detail)
  • Westhroid Use in Pregnancy & Breastfeeding
  • Westhroid Drug Interactions
  • Westhroid Support Group
  • 3 Reviews for Westhroid - Add your own review/rating


  • Westhroid Advanced Consumer (Micromedex) - Includes Dosage Information

  • Armour Thyroid Prescribing Information (FDA)

  • Armour Thyroid MedFacts Consumer Leaflet (Wolters Kluwer)



Compare Westhroid with other medications


  • Hashimoto's disease
  • Hypothyroidism, After Thyroid Removal
  • Thyroid Cancer
  • TSH Suppression
  • Underactive Thyroid


Where can I get more information?


  • Your pharmacist can provide more information about desiccated thyroid.

See also: Westhroid side effects (in more detail)


Tuesday, October 18, 2016

Westcort



hydrocortisone valerate

Dosage Form: cream

For Dermatologic Use Only. Not for Ophthalmic Use.



Westcort Description


Westcort® (hydrocortisone valerate cream) Cream, 0.2% contains hydrocortisone valerate, 11,21-dihydroxy-17-[(1-oxopentyl)oxy]-(11β)-pregn-4-ene-3,20-dione, a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents. Chemically, hydrocortisone valerate is C26H38O6. It has the following structural formula:



Hydrocortisone valerate has a molecular weight of 446.58. It is a white, crystalline solid, soluble in ethanol and methanol, sparingly soluble in propylene glycol and insoluble in water.


Each gram of Westcort Cream contains 2.0 mg hydrocortisone valerate in a hydrophilic base composed of amphoteric-9, carbomer 940, dried sodium phosphate, propylene glycol, sodium lauryl sulfate, sorbic acid, stearyl alcohol, water and white petrolatum.



Westcort - Clinical Pharmacology


Like other topical corticosteroids, hydrocortisone valerate has anti-inflammatory, antipruritic and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.



Pharmacokinetics


The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle and the integrity of the epidermal barrier. Occlusive dressings with hydrocortisone for up to 24 hours have not been demonstrated to increase penetration; however, occlusion of hydrocortisone for 96 hours markedly enhances penetration. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption.


Studies performed with Westcort Cream indicate that it is in the medium range of potency as compared with other topical corticosteroids.



Indications and Usage for Westcort


Westcort Cream is a medium potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in adult patients.



Contraindications


Westcort Cream is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.



Precautions



General


Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on treatment.


Patients applying a topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression. This may be done by using the ACTH stimulation, A.M. plasma cortisol, and urinary free cortisol tests.


Westcort Cream has produced mild, reversible adrenal suppression in adult patients when used under occlusion for 5 days, 15 grams twice a day over 25 to 60% body surface area or when used three times a day over 20 to 30% body surface area to treat psoriasis for 3-4 weeks.


If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid. Recovery of HPA axis function is generally prompt upon discontinuation of topical corticosteroids. Infrequently, signs and symptoms of glucocorticosteroid insufficiency may occur, requiring supplemental systemic corticosteroids. For information on systemic supplementation, see prescribing information for these products.


Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios. (See PRECAUTIONS: Pediatric Use.)


If irritation develops, Westcort® (hydrocortisone valerate cream) Cream, 0.2% should be discontinued and appropriate therapy instituted. Allergic contact dermatitis with corticosteroids is usually diagnosed by observing a failure to heal rather than noting a clinical exacerbation, as with most topical products not containing corticosteroids. Such an observation should be corroborated with appropriate diagnostic patch testing.


If concomitant skin infections are present or develop, an appropriate antifungal or antibacterial agent should be used. If a favorable response does not occur promptly, use of Westcort Cream should be discontinued until the infection has been adequately controlled.



Information for Patients


Patients using topical corticosteroids should receive the following information and instructions:


1)

This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.

2)

This medication should not be used for any disorder other than that for which it was prescribed.

3)

The treated skin area should not be bandaged, otherwise covered or wrapped, so as to be occlusive unless directed by the physician.

4)

Patients should report to their physician any signs of local adverse reactions.

5)

Westcort Cream should not be applied in the diaper areas as diapers or plastic pants may constitute occlusive dressings. (See DOSAGE AND ADMINISTRATION.)

6)

This medication should not be used on the face, underarms, or groin areas unless directed by the physician.

7)

As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, contact the physician.


Laboratory Tests


The following tests may be helpful in evaluating patients for HPA axis suppression:


 

ACTH stimulation test

 

A.M. plasma cortisol test

 

Urinary free cortisol test


Carcinogenesis, Mutagenesis, and Impairment of Fertility


Long-term animal studies have not been performed to evaluate the carcinogenic potential of hydrocortisone valerate. Westcort Cream was shown to be non-mutagenic in the Ames-Salmonella/Microsome Plate Test. There are no studies which assess the effects of hydrocortisone valerate on fertility and general reproductive performance.



Pregnancy: Teratogenic Effects, Pregnancy Category C


Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals.


Dermal embryofetal developmental studies were conducted in rabbits and rats with hydrocortisone valerate cream, 0.2%. Hydrocortisone valerate cream, 0.2%, was administered topically for 4 hours/day, rather than the preferred 24 hours/day, during the period of organogenesis in rats (gestational days 5-16) and rabbits (gestational days 6-19). Topical doses of hydrocortisone valerate up to 9 mg/kg/day (54 mg/m2/day) were administered to rats and 5 mg/kg/day (60 mg/m2/day) were administered to rabbits. In the absence of maternal toxicity, a significant increase in delayed skeletal ossification in fetuses was noted at 9 mg/kg/day [2.5X the Maximum Recommended Human Dose (MRHD) based on body surface area (BSA) comparisons] in the rat study. No malformations in the fetuses were noted at 9 mg/kg/day (2.5X MRHD based on BSA comparisons) in the rat study. Indicators of embryofetal toxicity, significant decrease in fetal weight at 2 mg/kg/day (1X MRHD based on BSA) and a significant increase in post-implantation loss and embryo resorption at 5 mg/kg (3X MRHD based on BSA), were noted in the rabbit study. A significant increase in delayed skeletal ossification in fetuses was noted at 5 mg/kg/day (3X the MRHD based on BSA comparisons) in the rabbit study. Increased numbers of fetal malformations (e.g., cleft palate, omphalocele and clubbed feet) were noted at 5 mg/kg/day (3X MRHD based on BSA comparisons) in the rabbit study.


There are no adequate and well-controlled studies in pregnant women. Westcort® (hydrocortisone valerate cream) Cream, 0.2% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.



Nursing Mothers


Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when Westcort Cream is administered to a nursing woman.



Pediatric Use


Safety of this product in pediatric patients has not been established. There is no data on adrenal suppression and/or growth suppression.


Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression and Cushing’s syndrome when they are treated with topical corticosteroids. They are therefore also at a greater risk of adrenal insufficiency during and/or after withdrawal of treatment. Adverse effects including striae have been reported with inappropriate use of topical corticosteroids in infants and children. (See PRECAUTIONS.)


HPA axis suppression, Cushing’s syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol levels, and an absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.



Geriatric Use


Clinical studies of Westcort Cream did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.



Adverse Reactions


The following local adverse reactions have been reported with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.


In controlled clinical studies involving pediatric patients one month to 2 years of age (n=29), the incidence of adverse experiences, regardless of relationship to the use of Westcort Cream, was approximately 21%. Reported reactions included stinging (10%), eczema (7%), fungal infection (3%), and gastrointestinal disorder (3%).


In controlled clinical studies involving pediatric patients 2 to 12 years of age (n=153), the incidence of adverse experiences, regardless of relationship to the use of Westcort Cream, was approximately 10%. Reported reactions included stinging (3%), burning skin (2%), infection (Body as a Whole) (2%). Skin irritation, eczema, pruritus, application site reaction, rash, rash maculopapular, and dry skin were all reported at incidences of approximately 1%.



Overdosage


Topically applied Westcort Cream can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS).



Westcort Dosage and Administration


Westcort Cream should be applied to the affected area as a thin film two or three times daily depending on the severity of the condition.


As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary.


Westcort Cream should not be used with occlusive dressings unless directed by a physician. Westcort Cream should not be applied in the diaper area if the patient requires diapers or plastic pants as these garments may constitute occlusive dressing.



How is Westcort Supplied


Westcort® (hydrocortisone valerate cream) Cream, 0.2%, is supplied in the following tube sizes:


 

15 g NDC 0072-8100-15: NSN 6505-01-093-9901

 

45 g NDC 0072-8100-45: NSN 6505-01-083-9395

 

60 g NDC 0072-8100-60: NSN 6505-01-121-0118


STORAGE


Store between 20° C-25° C (68° F-77° F); excursions permitted between 15° C and 30° C.



Distributed by:

Westwood-Squibb Pharmaceuticals, Inc.

A Bristol-Myers Squibb Company

Princeton, NJ 08543 USA


51-022263-01

Revised April 2006








Westcort 
hydrocortisone valerate  cream










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)0072-8100
Route of AdministrationTOPICALDEA Schedule    



































INGREDIENTS
Name (Active Moiety)TypeStrength
hydrocortisone valerate (hydrocortisone)Active2 MILLIGRAM  In 1 GRAM
amphoteric-9Inactive 
carbomer 940Inactive 
dried sodium phosphateInactive 
propylene glycolInactive 
sodium lauryl sulfateInactive 
sorbic acidInactive 
stearyl alcoholInactive 
waterInactive 
white petrolatumInactive 


















Product Characteristics
Color    Score    
ShapeSize
FlavorImprint Code
Contains      






























Packaging
#NDCPackage DescriptionMultilevel Packaging
10072-8100-151 TUBE In 1 CARTONcontains a TUBE
115 g (GRAM) In 1 TUBEThis package is contained within the CARTON (0072-8100-15)
20072-8100-451 TUBE In 1 CARTONcontains a TUBE
245 g (GRAM) In 1 TUBEThis package is contained within the CARTON (0072-8100-45)
30072-8100-601 TUBE In 1 CARTONcontains a TUBE
360 g (GRAM) In 1 TUBEThis package is contained within the CARTON (0072-8100-60)

Revised: 05/2007Bristol-Myers Squibb Company

More Westcort resources


  • Westcort Side Effects (in more detail)
  • Westcort Use in Pregnancy & Breastfeeding
  • Westcort Drug Interactions
  • Westcort Support Group
  • 1 Review for Westcort - Add your own review/rating


  • Westcort Topical application Advanced Consumer (Micromedex) - Includes Dosage Information

  • Westcort Cream MedFacts Consumer Leaflet (Wolters Kluwer)

  • Westcort Concise Consumer Information (Cerner Multum)

  • Anucort-HC cream, ointment, suppository Concise Consumer Information (Cerner Multum)

  • Anusol-HC Cream MedFacts Consumer Leaflet (Wolters Kluwer)

  • Carmol HC Concise Consumer Information (Cerner Multum)

  • Carmol HC MedFacts Consumer Leaflet (Wolters Kluwer)

  • Cortizone-10 Cream MedFacts Consumer Leaflet (Wolters Kluwer)

  • Hydrocortisone Acetate Monograph (AHFS DI)

  • Hydrocortisone with Aloe Cream MedFacts Consumer Leaflet (Wolters Kluwer)

  • Instacort Gel MedFacts Consumer Leaflet (Wolters Kluwer)

  • Nutracort Concise Consumer Information (Cerner Multum)

  • Nutracort Lotion MedFacts Consumer Leaflet (Wolters Kluwer)

  • Pediaderm HC Lotion MedFacts Consumer Leaflet (Wolters Kluwer)

  • ProctoCream-HC Cream MedFacts Consumer Leaflet (Wolters Kluwer)



Compare Westcort with other medications


  • Anal Itching
  • Aphthous Stomatitis, Recurrent
  • Atopic Dermatitis
  • Dermatitis
  • Eczema
  • Gingivitis
  • Proctitis
  • Pruritus
  • Psoriasis
  • Seborrheic Dermatitis
  • Skin Rash
  • Ulcerative Colitis, Active

WinRho





Dosage Form: injection
FULL PRESCRIBING INFORMATION
WARNING: INTRAVASCULAR HEMOLYSIS (IVH)

This warning does not apply to Rho(D)-negative patients treated for the suppression of Rh isoimmunization.


  • Intravascular hemolysis (IVH) leading to death has been reported in patients treated with WinRho® SDF for immune thrombocytopenic purpura (ITP).

  • IVH can lead to clinically compromising anemia and multi-system organ failure including acute respiratory distress syndrome (ARDS).

  • Serious complications including severe anemia, acute renal insufficiency, renal failure and disseminated intravascular coagulation (DIC) have also been reported.

  • Closely monitor patients treated with WinRho® SDF for ITP in a healthcare setting for at least eight hours after administration. A dipstick urinalysis to monitor for hematuria and hemoglobinuria is to be performed at baseline and then after administration at 2 hours, 4 hours and prior to the end of the monitoring period. Alert patients and monitor the signs and symptoms of IVH including back pain, shaking chills, fever, and discolored urine or hemoglobinuria. Absence of these signs and/or symptoms of IVH within eight hours do not indicate IVH cannot occur subsequently. If signs and/or symptoms of IVH are present or suspected after WinRho® SDF administration, post-treatment laboratory tests should be performed including plasma hemoglobin, haptoglobin, LDH, and plasma bilirubin (direct and indirect).



Indications and Usage for WinRho


WinRho® SDF is an Rho(D) Immune Globulin Intravenous (Human) (anti-D) product that is indicated for the treatment of ITP in Rho(D)-positive patients and for the suppression of Rh isoimmunization in non-sensitized Rho(D)-negative patients.



Treatment of ITP


WinRho® SDF is indicated for use in clinical situations requiring an increase in platelet count to prevent excessive hemorrhage in the treatment of non-splenectomized, Rho(D)-positive


  • children with chronic or acute ITP,

  • adults with chronic ITP, or

  • children and adults with ITP secondary to HIV infection

The safety and efficacy of WinRho® SDF have not been evaluated in clinical trials for patients with non-ITP causes of thrombocytopenia or in previously splenectomized patients or in patients who are Rho(D)-negative.



Supression of Rh Isoimmunization


Pregnancy and Other Obstetric Conditions


WinRho® SDF is indicated for the suppression of Rh isoimmunization in non-sensitized, Rho(D)-negative (D-negative) women with an Rh-incompatible pregnancy, including:


  • Routine antepartum and postpartum Rh prophylaxis

  • Rh prophylaxis in cases of:
    • Obstetric complication (e.g., miscarriage, abortion, threatened abortion, ectopic pregnancy or hydatidiform mole, transplancental hemorrhage resulting from antepartum hemorrhage)

    • Invasive procedures during pregnancy (e.g., amniocentesis, chorionic biopsy) or obstetric manipulative procedures (e.g., external version, abdominal trauma)


An Rh-incompatible pregnancy is assumed if the fetus/baby is either Rho(D)-positive or Rho(D)-unknown or if the father is either Rho(D)-positive or Rho(D)-unknown.


Incompatible Transfusions


WinRho® SDF is indicated for the suppression of Rh isoimmunization in Rho(D)-negative individuals transfused with Rho(D)-positive red blood cells (RBCs) or blood components containing Rho(D)-positive RBCs.


WinRho®SDF is not indicated for use as immunoglobulin replacement therapy for immune globulin deficiency syndromes.



WinRho Dosage and Administration



Preparation and Handling


  • Bring WinRho® SDF to room temperature prior to use.

  • Inspect WinRho® SDF for particulate matter and discoloration prior to administration. Do not use if the solution is cloudy or contains particulates.

  • WinRho® SDF is for single use only. Discard any unused portion.

  • The solution is ready to use, no reconstitution required. See Table 1 for the target fill volumes for each of the dosage sizes for WinRho® SDF.















Table 1 Liquid WinRho® SDF Dosage size and target fill volumes
Vial SizeTarget Fill Volume
600 international unit (120 mcg)0.5 mL
1,500 international unit (300 mcg)1.3 mL
2,500 international unit (500 mcg)2.2 mL
5,000 international unit (1,000 mcg)4.4 mL
15,000 international unit (3,000 mcg)13.0 mL

Note: Remove the entire contents of the vial to obtain the labelled dosage of WinRho® SDF. If partial vials are required for dosage calculation, withdraw the entire contents of the vial to ensure accurate calculation of the dosage requirement. For ease in withdrawing the contents of the vial, draw back the plunger of a sterile syringe (with the needle and needle cover in place) to admit air into the syringe. Depress the plunger of the syringe to inject air into the vial. Invert vial and aspirate contents of vial into syringe.



Treatment of ITP


ADMINISTER WinRho®  SDF BY THE INTRAVENOUS ROUTE ONLY (see Preparation and Handling [2.1] ). Do not administer intramuscularly.


  • Administer the entire dose of WinRho® SDF into a suitable vein over three to five minutes.

  • Administer WinRho® SDF separately from other drugs.

  • If dilution of WinRho SDF is preferred prior to intravenous administration, use normal saline as diluent. Do not use Dextrose (5%) in water (D5W). No other diluents have been tested.

Initial Dosing: An initial dose of 250 international unit/kg (50 mcg/kg) body weight, given as a single injection is recommended for the treatment of ITP. The initial dose may be administered in two divided doses given on separate days, if desired. If the patient has a hemoglobin level less than 10 g/dL, a reduced dose of 125 to 200 international unit/kg (25 to 40 mcg/kg) should be given to minimize the risk of increasing the severity of anemia in the patient. All patients should be monitored to determine clinical response by assessing platelet counts, RBCs, hemoglobin (Hgb), and reticulocyte levels [see ].


Subsequent Dosing: If subsequent therapy is required to elevate platelet counts, an intravenous dose of 125 to 300 international unit/kg (25 to 60 mcg/kg) body weight of WinRho® SDF is recommended. The frequency of dosing and the dose used in maintenance therapy should be determined by the patient’s clinical response by assessing platelet counts, RBCs, Hgb, and reticulocyte levels.


If a patient responded to initial dose with a satisfactory increase in platelets, maintenance dose at 125 to 300 international unit/kg (25 to 60 mcg/kg), individualized based on platelet and Hgb levels. An international consensus report on the investigation and management of primary immune thrombocytopenia states that treatment is rarely indicated in patients with platelet counts above 50 x 109/L and this has been generally accepted as the threshold for satisfactory response.1 Evaluate whether patient responded with a satisfactory increase in platelets based on the clinical situation and bleeding risks for the individual patient.


If patient did not respond to initial dose, administer a subsequent dose based on Hgb:


If Hgb between 8-10 g/dL, redose between 125 to 200 international unit/kg (25 to 40 mcg/kg).


If Hgb >10 g/dL, redose between 250 to 300 international unit/kg (50 to 60 mcg/kg).


If Hgb < 8 g/dL, alternative treatments should be used.


The following equations are provided to determine the dosage and number of vials needed for the treatment of ITP:


  • weight in lbs/2.21 = weight in kg

  • weight in kg X selected international unit (mcg) dosing level = dosage

  • dosage / vial size = number of vials needed

Safety and efficacy of WinRho® SDF  in the treatment of ITP at doses exceeding 300 international unit/kg (60 mcg/kg) has not been established.



Supression of Rh Isoimmunization


Intravenous or intramuscular use.


  • For intravenous administration, administer WinRho® SDF separately from other drugs. WinRho® SDF should be administered at a rate of 2 mL per 5 to 15 seconds.

  • For intramuscular administration, administer into the deltoid muscle of the upper arm or the anterolateral aspects of the upper thigh. Due to the risk of sciatic nerve injury, avoid the gluteal region. If the gluteal region is used, use only the upper, outer quadrant.

Pregnancy and other Obstetric Indications


Table 2 provides dosing guidelines based on the condition being treated.

























Table 2 Obstetric Indications and Recommended Dose
IndicationTiming of Administration

Dose


(Administer IM or IV)
Rh-incompatible Pregnancy:
Routine antepartum prophylaxis28 weeks gestation*1,500 international unit (300 mcg)

Postpartum


(if newborn is Rho(D)-positive)
Within 72 hours of birth**600 international unit (120 mcg)
Obstetric Conditions:
Threatened abortion at any timeImmediately1,500 international unit (300 mcg)
Amniocentesis and chorionic villus sampling before 34 weeks gestationImmediately after procedure†1,500 international unit (300 mcg)
Abortion, amniocentesis, or any other manipulation after 34 weeks gestationWithin 72 hours600 international unit (120 mcg)

* If WinRho® SDF is administered early in the pregnancy, it is recommended that WinRho® SDF be administered at 12-week intervals in order to maintain adequate levels of passively acquired anti-Rh.


** In the event that the Rh status of the baby is not known at 72 hours, WinRho® SDF should be administered to the mother at 72 hours after delivery. If more than 72 hours have elapsed, WinRho® SDF should not be withheld but administered as soon as possible up to 28 days after delivery.


†Repeat every 12 weeks during pregnancy

 Incompatible Transfusion


Administer WinRho® SDF within 72 hours after exposure for treatment of incompatible blood transfusions or massive fetal hemorrhage.


Table 3 provides dosing guidelines based on the condition being treated.



















Table 3 Transfusion Indication and Recommended Dose
Route of AdministrationRate of AdministrationWinRho® SDF Dose
If exposed to Rho(D)-Positive Whole Blood:If exposed to Rho(D)-Positive Red Blood Cells:  
Intravenous3,000 international unit (600 mcg) every 8 hours45 international unit (9 mcg)/mL blood90 international unit (18 mcg)/mL cells
Intramuscular6,000 international unit (1,200 mcg) every 12 hours60 international unit (12 mcg)/mL blood120 international unit (24 mcg)/mL cells

Dosage Forms and Strengths


WinRho SDF, RhO(D) Immune Globulin Intravenous (Human), is available as a ready to use solution for injection available in single dose vials of 600 international unit (120 mcg), 1,500 international unit (300 mcg), 2,500 international unit (500 mcg), 5,000 international unit (1000 mcg) and 15,000 international unit (3,000 mcg).



Contraindications


WinRho® SDF is contraindicated in:


  • Patients who have had known anaphylactic or severe systemic reaction to the administration of human immune globulin products.

  • IgA deficient patients with antibodies to IgA and a history of hypersensitivity.

  • Patients with autoimmune hemolytic anemia, with pre-existing hemolysis or at high risk for hemolysis.

  • Infants for the suppression of Rho(D) isoimmunization.


Warnings and Precautions



Both Indications


5.1.1 Hypersensitivity


Severe hypersensitivity reactions may occur [see Contraindications (4)] If symptoms of allergic or early signs of hypersensitivity reactions (including generalized urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis) occur, discontinue WinRho® SDF infusion immediately and institute appropriate treatment. Have medications such as epinephrine available for immediate treatment of acute hypersensitivity reactions.


WinRho® SDF contains approximately 5 micrograms/mL IgA [see Description (11)]. Patients with known antibodies to IgA have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions. WinRho® SDF is contraindicated in patients with antibodies against IgA and a history of hypersensitivity reaction [see Contraindications (4)].


5.1.2 Transmissible Infectious Agents


Because WinRho® SDF is made from human plasma; it may carry a risk of transmitting infectious agents, e.g., viruses and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. The risk of transmitting an infectious agent has been reduced by screening plasma donors for prior exposure to certain pathogens, testing for the presence of certain current viral infections, and including virus inactivation/removal steps in the manufacturing process [see Description (11)]


Report all infections thought to have been transmitted by WinRho® SDF to Cangene Corporation at 1-800-768-2304. The physician should discuss the risks and benefits of this product with the patient.


5.1.3 Interference with Blood Glucose Testing: False High Blood Glucose Levels


The liquid formulation of WinRho® SDF contains maltose. Maltose in IGIV products has been shown to give falsely high blood glucose levels in certain types of blood glucose testing systems [for example, by systems based on glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ) or glucose-dye-oxidoreductase methods]. Due to the potential for falsely elevated glucose readings, only use testing systems that are glucose-specific to test or monitor blood glucose levels in patients receiving maltose-containing parenteral products, including WinRho® SDF Liquid.


Carefully review the product information of the blood glucose testing system, including that of the test strips, to determine if the system is appropriate for use with maltose-containing parenteral products. If any uncertainty exists, contact the manufacturer of the testing system to determine if the system is appropriate for use with maltose-containing parenteral products.


5.1.4 Renal Dysfunction/Failure


Acute renal dysfunction/failure, osmotic nephropathy, and death may occur upon use of Immune Globulin Intravenous (IGIV) products, including WinRho® SDF.2 Ensure that patients are not volume depleted before administering WinRho® SDF. For patients at risk of renal dysfunction or failure, including those with any degree of pre-existing renal insufficiency, diabetes mellitus, advanced age (above 65 years of age), volume depletion, sepsis, paraproteinemia, or receiving known nephrotoxic drugs, administer WinRho® SDF at the minimum infusion rate practicable.


Assess renal function, including measurement of blood urea nitrogen (BUN) and serum creatinine, before the initial infusion of WinRho® SDF.


5.1.5 Thromboembolic Events


Thromboembolic events may occur during or following treatment with WinRho® SDF and other IGIV products.3,4 Patients at risk include those with a history of atherosclerosis, multiple cardiovascular risk factors, advanced age, impaired cardiac output, coagulation disorders, prolonged periods of immobilization, and/or known/suspected hyperviscosity.


Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity including those with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies. For patients who are at risk of developing thromboembolic events, administer WinRho® SDF at the minimum rate of infusion practicable.


5.1.6 Interference with Serological Testing


After administration of WinRho® SDF, a transitory increase of various passively transferred antibodies in the patient’s blood may yield positive serological testing results, with the potential for misleading interpretation. Passive transmission of antibodies to erythrocyte antigens (e.g., A, B, C and E) and other blood group antibodies [for example, anti Duffy, anti Kidd (anti JKa) antibodies]5 may cause a positive direct or indirect (Coombs’) test.


A large fetomaternal hemorrhage late in pregnancy or following delivery may cause a weak mixed field positive Du test result. Assess such an individual for a large fetomaternal hemorrhage and adjust the dose of WinRho® SDF accordingly. The presence of passively administered anti Rho(D) in maternal or fetal blood can lead to a positive direct Coombs’ test. If there is an uncertainty about the father’s Rh group or immune status, administer WinRho® SDF to the mother.


5.1.7 Transfusion-Related Acute Lung Injury (TRALI)


Non-cardiogenic pulmonary edema may occur in patients following IGIV treatment, including WinRho® SDF.6 TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, normal left ventricular function, and fever. Symptoms typically appear within 1 to 6 hours following administration of blood products.


Monitor patients for pulmonary adverse reaction. If TRALI is suspected, perform appropriate tests for the presence of anti-neutrophil antibodies and anti-HLA antibodies in both the product and patient serum. TRALI may be managed using oxygen therapy with adequate ventilatory support.


5.1.8 Monitoring Laboratory Tests


  • For all ITP patients, blood type, blood count, reticulocyte count, DAT and dipstick urinalysis are recommended before deciding to treat patients with WinRho® SDF. In patients with evidence of hemolysis (reticulocytosis greater than 3%), or patients at risk of hemolysis (positive DAT not attributed to previous immune globulin administration) use other treatments.1

  • Closely monitor patients administered WinRho® SDF for at least 8 hours post administration and perform a dipstick urinalysis to monitor for hematuria and hemoglobinuria at baseline and then after administration at 2 hours, 4 hours and prior to the end of the monitoring period.

  • If signs and/or symptoms of IVH and its complications are present after anti-D administration, perform appropriate confirmatory laboratory testing including, but not limited to, CBC (i.e. hemoglobin, platelet counts), haptoglobin, plasma hemoglobin, urine dipstick, assessment of renal function (i.e. BUN, serum creatinine), liver function (i.e. LDH, direct and indirect bilirubin) and DIC specific tests such as D-dimer or Fibrin Degradation Products (FDP) or Fibrin Split Products (FSP).

  • Periodic monitoring of renal function and urine output in patients who are at increased risk of developing acute renal failure [see Warnings and Precautions (5.1.4)]. Assess renal function in these at-risk patients, including measurement of BUN and serum creatinine, before the initial infusion of WinRho® SDF and at appropriate intervals thereafter.

  • If TRALI is suspected in ITP patients, perform appropriate tests for the presence of anti-neutrophil antibodies in both the product and patient serum [see Warnings and Precautions (5.1.7)].


Treatment of ITP


5.2.1 Intravascular Hemolysis (IVH)


IVH leading to death has been reported in patients treated for ITP with WinRho® SDF.


IVH can lead to clinically compromising anemia and multi-system organ failure including acute respiratory distress syndrome (ARDS).


Serious complications including severe anemia, acute renal insufficiency, renal failure and disseminated intravascular coagulation (DIC) have also been reported.7,8


Closely monitor patients treated with WinRho® SDF for ITP in a healthcare setting for at least eight hours after administration. Peform a dipstick urinalysis to monitor for hematuria and hemoglobinuria at baseline and then after administration at 2 hours, 4 hours and prior to the end of the monitoring period. Alert patients and monitor for signs and symptoms of IVH including back pain, shaking chills, fever, and discolored urine or hemoglobinuria. Absence of these signs and/or symptoms of IVH within eight hours do not indicate IVH cannot occur subsequently. If signs and/or symptoms of IVH are present or if IVH is suspected after WinRho® SDF administration, perform post-treatment laboratory tests including plasma hemoglobin, haptoglobin, LDH, and plasma bilirubin (direct and indirect).


5.2.2 Hemolysis


Although the mechanism of action of WinRho® SDF in the treatment of ITP is not completely understood it is postulated that anti-D binds to the Rho(D) RBC resulting in formation of antibody-coated RBC complexes. Immune-mediated clearance of the antibody-coated RBC complexes would spare the antibody-coated platelets because of the preferential destruction of antibody-coated RBC complexes by the macrophages located in the reticuloendothelial system.9-11 The side effect of this action is a decrease in hemoglobin levels (extravascular hemolysis).7 The pooled data from ITP clinical studies demonstrated a mean decrease from baseline in hemoglobin levels of 1.2 g/dL within 7 days after administration of WinRho®SDF.


If the patient has lower than normal hemoglobin levels (less than 10 g/dL), a reduced dose of 125 to 200 international unit/kg (25 to 40 mcg/kg) should be given to minimize the risk of increasing the severity of anemia in the patient. Alternative treatments should be used in patients with hemoglobin levels that are less than 8 g/dL due to the risk of increasing the severity of the anemia [see Dosage and Administration (2.2)].


Significant anemia may present with pallor, hypotension, or tachycardia while acute renal insufficiency may present with oliguria or anuria, edema and dyspnea. Patients with IVH who develop DIC may exhibit signs and symptoms of increased bruising and prolongation of bleeding time and clotting time which may be difficult to detect in the ITP population. Consequently the diagnosis of this serious complication of IVH is dependent on laboratory testing [see Warnings and Precautions (5.1.7)]. Previous uneventful administration of WinRho® SDF does not preclude the possibility of an occurrence of IVH and its complications following any subsequent administration of WinRho® SDF. Have confirmatory laboratory testing on ITP patients presenting with signs and/or symptoms of IVH and its complications after anti-D administration [see Warnings and Precautions (5.1.7)].


If ITP patients are to be transfused, use Rho(D)-negative red blood cells (PRBCs) so as not to exacerbate ongoing hemolysis.



Supression of Rh Isoimmunization


Do not administer WinRho® SDF to Rho(D)-negative individuals who are Rh immunized as evidenced by an indirect antiglobulin (Coombs’) test revealing the presence of anti-Rho(D) (anti-D) antibody. For postpartum use following an Rh-incompatible pregnancy administer WinRho® SDF to the mother only. Do not administer to the newborn infant.



Adverse Reactions


Serious adverse reactions, some of these cases resulted in fatal outcome, have been observed in patients receiving WinRho® SDF for the treatment of ITP. These include: intravascular hemolysis (IVH), clinically compromising anemia, acute renal insufficiency and DIC [see Adverse Reactions, (6.2)].


The most common adverse reactions observed for all indications are: headache, chills, fever, asthenia, pallor, diarrhea, nausea, vomiting, arthralgia, myalgia, dizziness, hyperkinesia, abdominal or back pain, hypotension, hypertension, increased LDH, somnolence, vasodilation, pruritus, rash and sweating. All adverse reactions listed occurred in ≤ 2% of WinRho® doses administered in clinical trials.


Adverse reactions observed in the use of WinRho® SDF for Suppression of Rh Isoimmunization are <0.1% in Rho(D)-negative individuals.



Clinical Trials Experiences


Because clinical studies are conducted under different protocols and widely varying conditions, adverse reaction rates observed in the clinical trials of a specific drug product cannot be directly compared to rates in clinical trials of another drug, and may not reflect rates observed in practice.


Treatment of ITP


The safety of WinRho SDF was evaluated in clinical trials (n=161) in children and adults with acute and chronic ITP and adults and children with ITP secondary to HIV. Overall, 417 adverse events were reported by 91 patients (57%). The most common adverse events were headache (14% of the patients), fever (11% of the patients) and asthenia (11% of the patients). A total of 117 adverse drug reactions were re ported by 46 patients (29%). Headache, chills, and fever were the most common related adverse events (Table 4). With respect to safety profile per administration, 60/848 (7%) of WinRho® infusions had at least one adverse reaction. The most common adverse reactions were headache (19 infusions; 2%), chills (14 infusions; < 2%), and fever (nine infusions; 1%).








































Table 4 Adverse drug Reaction s with an Incidence ≥5% of Patients
Body SystemAdverse EventAll StudiesChildrenAdults
# of Patients (%)
Body as a WholeHeadache18 (11)8 (11)10 (12)
Chills13 (8)4 (5)9 (10) 
Fever9 (6)5 (7)4 (5) 
Asthenia6 (4)2 (3)4 (5) 
Infection4 (3)4 (5)0 (0) 
Nervous SystemDizziness6 (4)2 (3)4 (5)

 


In four clinical trials of patients treated with the recommended initial intravenous dose of 250 international unit/kg (50 mcg/kg), the mean maximum decrease in hemoglobin was 1.70 g/dL (range: +0.40 to -6.1g/dL). At a reduced dose, ranging from 125 to 200 international unit/kg (25 to 40 mcg/kg), the mean maximum decrease in hemoglobin was 0.81 g/dL (range: +0.65 to -1.9 g/dL). Only 5/137 (3.7%) of patients had a maximum decrease in hemoglobin of greater than 4 g/dL (range: -4.2 to -6.1 g/dL).


Suppression of Rh Isoimmunization


In the clinical trial of 1,186 Rho(D)-negative pregnant women, no adverse reactions were reported to Rho(D) IGIV.



Post-marketing Experience


Because post-marketing adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to product exposure. The following adverse reactions have been identified during the post-approval use of WinRho®  SDF.


Treatment of ITP


These adverse reactions are classified by system organ class.


Intravascular hemolysis (IVH) leading to death has been reported in patients treated with WinRho® SDF for immune thrombocytopenic purpura (ITP).


Serious complications including severe anemia, acute renal insufficiency, renal failure and disseminated intravascular coagulation (DIC) have also been reported.


Infusion Reactions: Anaphylactic reaction, Hypersensitivity


Hematologic: Intravascular hemolysis, Disseminated Intravascular Coagulation, Hemoglobinemia


Cardiac: Cardiac arrest, Cardiac failure, Myocardial infarction, Tachycardia


Gastrointestinal: Nausea


General: Chest pain, Fatigue, Edema


Hepatologic: Jaundice


Musculoskeletal: Myalgia, Muscle spasm, Pain in extremities


Renal: Renal failure, Renal impairment, Anuria, Chromaturia, Hemoglobinuria, Hematuria


Respiratory: Acute respiratory distress syndrome, Transfusion related acute lung injury


Integumentary: Hyperhidrosis


Suppression of Rh Isoimmunization


Infusion Reactions: Hypersensitivity, anaphylactic reaction, induration, pruritus or swelling at injection site


Integumentary: Pruritus, Rash


Healthcare professionals should report serious adverse reactions following the administration of WinRho® SDF to Cangene Corporation at 1-800-768-2304 or FDA’s MedWatch reporting system by phone (1-800-FDA-1088).



Drug Interactions



Live Virus Vaccines


Administration of WinRho® SDF concomitantly with other drugs has not been evaluated. Passive transfer of antibodies may transiently impair the immune response to live attenuated virus vaccines such as measles, mumps, rubella, and varicella (see Patient Counseling Information [17.1]). Do not give immunization with live vaccines within 3 months after WinRho® SDF administration.



USE IN SPECIFIC POPULATIONS



Pregnancy


Pregnancy category C. Animal reproduction studies have not been conducted with WinRho® SDF. It is also not known whether WinRho® SDF can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. WinRho® SDF should be given to a pregnant woman only if clearly needed.


Treatment of ITP


WinRho® SDF has not been evaluated in pregnant women with ITP.


Suppression of Rh Isoimmunization


The available evidence suggests that WinRho® SDF does not harm the fetus or affect future pregnancies or reproduction capacity when given to pregnant Rho(D)-negative women for suppression of Rh isoimmunization.12



Nursing Mothers


Treatment of ITP


WinRho® SDF has not been evaluated in nursing mothers with ITP.


Suppression of Rh Isoimmunization


It is not known whether WinRho® SDF is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when WinRho SDF is administered to nursing women.



Pediatric Use


The safety and effectiveness of WinRho® has been evaluated for the treatment of chronic or acute ITP in children and in children (<16 years of age) with ITP secondary to HIV infection [see Adverse Reactions (6.2)]. The dosing recommendation in the treatment of children with ITP is the same as in adults [see Dosage and Administration (2.2)].



Geriatric Use


Clinical studies of WinRho® did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Post marketing clinical experience suggests that patients of advanced age (age over 65) with co-morbid conditions including but not limited to cardio-respiratory decompensation, renal failure or insufficiency or prothrombotic conditions are at increased risk of developing serious complications from acute hemolytic reactions such as IVH. Patients receiving doses in excess of 300 international unit/kg of WinRho® SDF may also be at an increased risk of developing increased hemolysis. Fatal outcomes associated with IVH and its complications have occurred most frequently in patients of advanced age (age over 65) with co-morbid conditions.


Use caution in dose selection for geriatric patients with consideration given to starting at the low end of the dosing range reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.



Overdosage


Treatment of ITP and Suppression of Rh Isoimmunization


In post-marketing spontaneous reporting, there has been a limited number of medication error reports related to dosage calculations in which higher doses than that recommended for WinRho® SDF were administered (doses > 60 mcg/kg). Signs and laboratory findings of overdosage in Rh positive (ITP) patients have included hemoglobin decreases in excess of 1.2 g/dL. For the suppression of Rh isoimmunization, hemolytic reactions have been reported in cases of mis-matched blood transfusions where very large doses of WinRho SDF were administered.


In one ITP case report that involved an overdose due to confusion between mcg and international unit, a patient with significant co-morbidities developed IVH and had a fatal outcome. In the event of overdose, monitor patients closely for signs and symptoms of hemolysis and initiate symptomatic and supportive treatment.



WinRho Description


WinRho® SDF is a sterile, liquid gamma globulin (IgG) fraction containing antibodies to the Rho(D) antigen (D antigen). WinRho® SDF is to be administered intravenously for the treatment of ITP and either intravenously or intramuscularly for the suppression of Rh isoimmunization.


WinRho® SDF is prepared from human plasma by an anion-exchange column chromatography method. The manufacturing process includes two steps implemented specifically for viral clearance. The solvent detergent treatment step (using tri-n-butyl phosphate and Triton® X-100) is effective in inactivating lipid enveloped viruses such as hepatitis B, hepatitis C, and HIV. Virus filtration, using a Planova™ 20N virus filter is effective in the removal of some non-lipid enveloped viruses. These two processes are designed to increase product safety by reducing the risk of transmission of enveloped and non-enveloped viruses, respectively. In addition to the two specific steps, the anion-exchange chromatography step contributes to the removal of small non-lipid enveloped viruses.


The inactivation and reduction of known enveloped and non-enveloped model viruses were validated in laboratory studies as summarized in Table 5.



























































Table 5 - Virus Reduction Values Obtained Through Validation Studies
EnvelopedEnvelopedNon-Enveloped
GenomeRNADNARNADNA
VirusHIV-1BVDVPRVHAVEMCMMVPPV
Familyretroflaviherpespicornaparvo
Size (nm)80-10050-70120-20025-303020-2518-24
Anion Exchange Chromatography (partitioning)Not evaluated2.3n.e.3.4n.e.
20N Filtration (size exclusion)≥ 4.7≥ 3.5≥ 5.6*n.e.4.8n.e.4.1
Solvent/Detergent (inactivation)≥ 4.7≥ 7.3≥ 5.5Not evaluated
Total Reduction (log10)≥ 9.4≥ 10.8≥ 11.17.17.5

* The PRV was retained by the 0.1 µm pre-filter during the virus validation. Since manufacturing employs a 0.1 µm pre-filter before the 20N filter, the claim of ≥5.6 reduction is considered applicable.


Abbreviations:


HIV-1: human immunodeficiency virus-1; relevant virus for human immunodeficiency virus-1 and model for HIV-2.


BVDV: bovine viral diarrhea virus; model virus for hepatitis C virus (HCV) and West Nile virus (WNV)


PRV: pseudorabies virus; model for large enveloped DNA viruses, including herpes


HAV: human hepatitis A virus; relevant virus for HAV and model for small non-enveloped viruses in general


EMC: encephalomyocarditis virus; model for HAV and for small non-enveloped viruses in general


MMV: murine minute virus; model for human parvovirus B19 and for small non-enveloped viruses in general


PPV: porcine parvovirus; model for human parvovirus B19 and for small non-enveloped viruses in general


n.e.: not evaluated


The product potency is expressed in international units by comparison to the World Health Organization (WHO) standard. In the past, a full dose of Rho(D) Immune Globulin (Human) has traditionally been referred to as a “300 microgram” dose. Potency and dosing recommendations are now expressed in international units by comparison to the WHO anti-Rho(D) standard. The conversion of “microgram” to “international units” is: 1 microgram = 5 international units. A 1,500 international unit (300 microgram [mcg]) vial contains sufficient anti-Rho(D) to effectively suppress the immunizing potential of approximately 17 mL of Rho(D) (D-positive) RBCs.


The liquid formulation is stabilized with 10% maltose and 0.03% polysorbate 80. There are no preservatives in the formulation. WinRho® SDF does not contain mercury. This product contains approximately 5 micrograms/mL IgA.



WinRho - Clinical Pharmacology



Mechanism of Action


Treatment of ITP


WinRho® SDF has been shown to increase platelet counts in non-splenectomized, Rho(D)-positive patients with ITP. Platelet counts usually rise within one to two days and peak within seven to 14 days after initiation of therapy. The mechanism of action is not completely understood, but is thought to be due to the formation of anti-Rho(D)-coated RBC complexes, which are preferentially removed by the reticuloendothelial system, particularly the spleen. This results in Fc receptor blockade, thus sparing antibody-coated platelets.9,10


Suppression of Rh Isoimmunization


The mechanism by which Rho(D) immune globulin suppresses immunization to Rho(D)-positive RBCs is not completely understood.


WinRho® SDF when administered within 72 hours of a full-term delivery of a Rho(D)-positive infant by a Rho(D) negative mother will reduce the incidence of Rh isoimmunization from 12-13% to 1-2%. The 1-2% is, for the most part, due to isoimmunization during the last trimester of pregnancy. When treatment is given both antenatally, at 28 weeks gestation, and postpartum, the Rh immunization rate drops to about 0.1%.13,14


When 600 international unit (120 mcg) of WinRho® SDF is administered to pregnant women, passive anti-Rho(D) antibodies are not detectable in the circulation for more than six weeks and therefore a dose of 1,500 international unit (300 mcg) should be used for antenatal administration.



Pharmacodynamics


In a clinical study with Rho(D)-negative volunteers (nine males and one female), Rho(D)-positive RBCs were completely cleared from the circulation within eight hours of intravenous administration of WinRho. There was no indication of Rh isoimmunization of these subjects at six m